AITRICS
Seoul
About AITRICS
AITRICS delivers AI-powered medical software designed to support clinicians in detecting and preventing critical patient deterioration. The company’s core product, AITRICS-VC (VitalCare), continuously monitors data from electronic medical records (EMRs), including vital signs, lab tests, consciousness levels, and other relevant clinical measurements to predict adverse events such as sepsis, cardiac arrest, unexpected ICU transfers, or mortality several hours before they occur. AITRICS-VC operates in real time, delivering risk scores and alerts to clinicians to enable earlier intervention and better resource allocation in hospital settings. The platform has been certified by the relevant regulatory authority in its home country and is classified as an “innovative medical device,” reflecting regulatory recognition of its predictive-analytics capabilities. In addition to monitoring and prediction, AITRICS engages in ongoing clinical validation and research; it publishes studies in peer-reviewed journals and presents its work in international AI conferences, indicating a commitment to evidence-based development and transparency in performance.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $50.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2025)
- Website: aitrics.com
- Phone: +82-2-569-5507
Industries & Categories
Analytics, Artificial Intelligence (AI), Health Care, Information Technology, Software
Social Profiles
Canonical: https://fsome.com/organization/aitrics-17083 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.